Bookmark and Share
BioAssay: AID 2476

Late stage probe development counterscreen for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence-based biochemical dose response assay for compounds that cause fluorescent intercalator displacement (FID)

Name: Late stage probe development counterscreen for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence-based biochemical dose response assay for compounds that cause fluorescent intercalator displacement (FID). ..more
_
   
 Tested Compounds
 Tested Compounds
All(8)
 
 
Inactive(8)
 
 
 Tested Substances
 Tested Substances
All(8)
 
 
Inactive(8)
 
 
 Related BioAssays
 Related BioAssays
AID: 2476
Data Source: The Scripps Research Institute Molecular Screening Center (DNAETBR_INH_FLINT_1536_3XIC50 LATE STAGE CSDRUN)
BioAssay Type: Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
Deposit Date: 2010-03-04
Hold-until Date: 2011-03-02
Modify Date: 2011-03-02

Data Table ( Complete ):           All
Tested Compounds:
Depositor Specified Assays
Show more
AIDNameTypeProbeComment
1800Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3)screening NS3 inhibition; single concentration in singlicate
1830Summary of probe development efforts to identify inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3).summary Summary (NS3 inhibition)
1845Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID)screening FID counterscreen; single concentration in singlicate
1943Fluorescence-based confirmation biochemical high throughput screening assay for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3)screening NS3 inhibition; single concentration in triplicate
1945Fluorescence-based counterscreen assay for HCV NS3 helicase inhibitors: biochemical high-throughput screening assay to identify compounds that cause fluorescent intercalator displacement (FID) in triplicate.screening FID counterscreen; single concentration in triplicate
2172Counterscreen for HCV NS3 helicase inhibitors: Fluorescence-based biochemical high-throughput dose response assay for compounds that cause fluorescent intercalator displacement (FID).confirmatory FID counterscreen; dose response in triplicate
2173Fluorescence-based biochemical high throughput dose response assay for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3).confirmatory NS3 inhibition; dose response in triplicate
602275Late stage probe development counterscreen for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): real-time florescence-based biochemical assay to determine whether compounds inhibit the helicase encoded by one or more HCV strains: Set 3other1
623966Late stage probe development assay for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): florescence polarization-based biochemical assay to determine whether compounds can displace the E. coli single stranded DNA binding proteinconfirmatory
623972Late stage probe development counterscreen for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): florescence-based biochemical assay with EtBr to determine whether compounds bind DNAconfirmatory
463235Late stage probe development assay for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): luminescence-based cell-based dose response assay to determine whether compounds inhibit replication of HCV RNA repliconconfirmatory
504419Late stage probe development counterscreen for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): real-time florescence-based biochemical assay to determine whether compounds inhibit the helicase encoded by one or more HCV strains: Set 2other
623962Late stage probe development assay for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): luminescence-based cell-based assay to determine whether compounds inhibit HCV replicationother
623968Late stage probe development assay for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): RT-PCR-based cell-based assay to determine the effect of compounds on RNA levelsconfirmatory
485301Late stage probe development counterscreen for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): real-time florescence-based biochemical assay to determine whether compounds inhibit the helicase encoded by one or more HCV strainsconfirmatory
623961Late stage probe development counterscreen for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): luminescence-based cell-based assay to determine cytotoxicity of compoundsother
623964Late stage probe development assay for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): florescence-based biochemical assay to determine whether compounds inhibit the HCV protease NS3-NS4Aconfirmatory
623970Late stage probe development counterscreen for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): florescence-based biochemical assay with SYBR to determine whether compounds bind DNAconfirmatory
623973Late stage probe development assay for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): absorbance-based biochemical assay to determine whether compounds inhibit ATPase activityconfirmatory
588360Late-stage probe development counterscreen for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): luminescence-based cell-based dose response assay to determine whether compounds that inhibit replication of HCV RNA replicon are cytotoxicconfirmatory
Description:
Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)
Center Affiliation: The Scripps Research Institute (TSRI)
Assay Provider: David Frick, New York Medical College
Network: Molecular Libraries Probe Production Centers Network (MLPCN)
Grant Proposal Number: 1 R03 MH085690-01
Grant Proposal PI: David Frick, New York Medical College
External Assay ID: DNAETBR_INH_FLINT_1536_3XIC50 LATE STAGE CSDRUN

Name: Late stage probe development counterscreen for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3): fluorescence-based biochemical dose response assay for compounds that cause fluorescent intercalator displacement (FID).

Description:

The flavivirus Hepatitis C Virus (HCV) is a major cause of liver failure and hepatocellular cancer, with about 170 million people infected worldwide (1). The HCV has a small RNA genome that is directly translated by the infected host cell into a single precursor polyprotein that is processed by enzymatic cleavage into 10 proteins of diverse function. The non-structural proteins include p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B, and are responsible for the replication and packaging of the HCV genome into capsids formed by the structural proteins (core, E1, E2)(2). Replication of HCV in human cells requires the action of the HCV non-structural protein 3 (NS3). This enzyme exhibits dual NTPase/helicase activities and functions to unwind DNA/DNA, RNA/RNA, and RNA/DNA duplexes by disrupting hydrogen bonds that hold the two strands together (3). The HCV NS3 helicase mediates the "active" form of duplex unwinding, and thus is dependent upon NTP and at least two nucleic acid binding sites on the NS3 surface (3). HCV NS3 is able to target homotypic and heterotypic duplexes because the interaction between the enzyme and the DNA or RNA substrate is mediated by phosphate groups and not by the nucleotide base or sugar moieties (4). The current absence of a vaccine to prevent HCV infection (5), along with knockout studies showing that the helicase and/or NTPase activities are essential for viral replication (6), and the lack of HCV genotype-specific differences in helicase residues and activities (7), support a role for NS3 as an important pathogenic component of HCV. The identification of specific inhibitors of HCV NS3 helicase will add insights into the biology of HCV infection and replication, and serve as valuable tools for inhibiting HCV replication in human cells.

References:

1. Hoofnagle, J.H., Course and outcome of hepatitis C. Hepatology, 2002. 36(5 Suppl 1): p. s21-s29.
2. Frick, D.N., The hepatitis C virus NS3 protein: a model RNA helicase and potential drug target. Curr Issues Mol Biol, 2007. 9(1): p. 1-20.
3. Borowski, P., Schalinski, S., and Schmitz, H., Nucleotide triphosphatase/helicase of hepatitis C virus as a target for antiviral therapy. Antiviral Res, 2002. 55(3): p. 397-412.
4. Kim, J.L., Morgenstern, K.A., Griffith, J.P., Dwyer, M.D., Thomson, J.A., Murcko, M.A., Lin, C., and Caron, P.R., Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure, 1998. 6(1): p. 89-100.
5. Yang, J.P., Zhou, D., and Wong-Staal, F., Screening of small-molecule compounds as inhibitors of HCV entry. Methods Mol Biol, 2009. 510: p. 295-304.
6. Gu, B., Liu, C., Lin-Goerke, J., Maley, D.R., Gutshall, L.L., Feltenberger, C.A., and Del Vecchio, A.M., The RNA helicase and nucleotide triphosphatase activities of the bovine viral diarrhea virus NS3 protein are essential for viral replication. J Virol, 2000. 74(4): p. 1794-800.
7. Cho, H.S., Ha, N.C., Kang, L.W., Chung, K.M., Back, S.H., Jang, S.K., and Oh, B.H., Crystal structure of RNA helicase from genotype 1b hepatitis C virus. A feasible mechanism of unwinding duplex RNA. J Biol Chem, 1998. 273(24): p. 15045-52.

Keywords:

late stage, HCV, NS3, NS3 helicase, hepatitis, RNA virus, dose response, counterscreen, triplicate, HTS, high throughput screen, 1536, inhibitor, inhibition, inhibit, ethidium bromide, FLINT, fluorescence, fluorescence intensity, FLINT, FID, fluorescence intercalator displacement, Scripps, Scripps Florida, The Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN.
Protocol
Assay Overview:

The purpose of this assay is to determine dose response curves for powders samples of compounds identified as active in a previous set of experiments entitled, "Counterscreen for HCV NS3 helicase inhibitors: Fluorescence-based biochemical high-throughput dose response assay for compounds that cause fluorescent intercalator displacement (FID)" (AID 2172). This assay also serves as a counterscreen for "Fluorescence-based biochemical high throughput dose response assay for inhibitors of the Hepatitis C Virus non-structural protein 3 helicase (NS3)" (2173) to determine whether the compounds are nonselective due to direct DNA binding. In this biochemical assay, a DNA hairpin oligonucleotide is incubated with test compound and a fluorescent intercalating agent, ethidium bromide. Upon binding to the DNA molecule, the fluorescence of the intercalating agent increases. As designed, test compounds that bind to the DNA molecule will compete with and displace the intercalating agent, resulting in a decrease in well fluorescence. Compounds were tested in triplicate in a 10-point 1:3 dilution series starting at a nominal test concentration of 79.4 micromolar.

Protocol Summary:

Prior to the start of the assay, 2.5 microliters of Assay Buffer (25 mM MOPS, pH 6.5) were dispensed into wells of a 1536 microtiter plate. Next, 40 nL of test compound in DMSO, diminazene aceturate (80 micromolar final concentration), or DMSO alone (0.6% final concentration) were added to the appropriate wells.

The assay was started by dispensing into all wells 2.5 microliters of Assay Buffer supplemented with 4 micromolar ethidium bromide and 0.32 micromolar hairpin oligonucleotide. Well fluorescence was read after 10 minutes of incubation at 25 degrees Celsius on the Viewlux (Perkin-Elmer). The percent inhibition for each well was then calculated as follows:

Percent Displacement = ( test_compound_Ratio_RFU - negative_control_Ratio_RFU ) / ( positive_control_Ratio_RFU - negative_control_Ratio_RFU ) * 100

Where:

Test_Compound is defined as wells containing test compound.
Negative_Control is defined as wells containing DMSO.
Positive_Control is defined as wells containing diminazene aceturate.

For each test compound, percent inhibition was plotted against compound concentration. A four parameter equation describing a sigmoidal dose-response curve was then fitted with adjustable baseline using Assay Explorer software (Symyx Technologies Inc). The reported IC50 values were generated from fitted curves by solving for the X-intercept value at the 50% inhibition level of the Y-intercept value. In cases where the highest concentration tested (i.e. 79.4 micromolar) did not result in greater than 50% inhibition, the IC50/ was determined manually as greater than 79.4 micromolar. Compounds with an IC50 greater than 10 micromolar were considered inactive. Compounds with an IC50 equal to or less than 10 micromolar were considered active.

Any compound with a percent activity value <50% at all test concentrations was assigned an activity score of zero. Any compound with a percent activity value >50% at any test concentration was assigned an activity score greater than zero. Activity score was then ranked by the potency, with the most potent compounds assigned the highest activity scores.

The PubChem Activity Score range for inactive compounds is 0-0. There are no actives.

List of Reagents:

DNA hairpin oligonucleotide (Integrated DNA Technologies Inc, custom synthesized)
Intercalating agent (Ethidium Bromide) (Bio-Rad, part 161-0433)
Diminazene Aceturate (Sigma-Aldrich, part D7770)
MOPS (Fisher-Biotech, part BP308-100)
1536-well plates (Greiner, part 789173)
Comment
This assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds, or required the calculation of hit cutoff on a plate-by-plate basis within a single HTS campaign. In this case the results of each separate campaign or plate within a single campaign were assigned "Active/Inactive" status based upon that campaign's specific compound activity cutoff value. In this assay, diminazene aceturate had an IC50 of approximately 1.6 micromolar. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided.
Result Definitions
Show more
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
1QualifierActivity Qualifier identifies if the resultant data IC50 came from a fitted curve or was determined manually to be less than or greater than its listed IC50 concentration.String
2IC50*The concentration at which 50 percent of the inhibition in the inhibitor assay is observed; (IC50) shown in micromolar.FloatμM
3LogIC50Log10 of the qualified IC50 (IC50) from the agonist assay in M concentrationFloat
4Hill SlopeThe variable HillSlope describes the steepness of the curve. This variable is called the Hill slope, the slope factor, or the Hill coefficient. If it is positive, the curve increases as X increases. If it is negative, the curve decreases as X increases. A standard sigmoid dose-response curve (previous equation) has a Hill Slope of 1.0. When HillSlope is less than 1.0, the curve is more shallow. When HillSlope is greater than 1.0, the curve is steeper. The Hill slope has no units.Float
5Hill S0Y-min of the curve.Float
6Hill SinfY-max of the curve.Float
7Hill dSThe range of Y.Float
8Chi SquareA measure for the 'goodness' of a fit. The chi-square test (Snedecor and Cochran, 1989) is used to test if a sample of data came from a population with a specific distribution.Float
9RsquareThis statistic measures how successful the fit explains the variation of the data; R-square is the square of the correlation between the response values and the predicted response values.Float
10Number of DataPointsOverall number of data points of normalized percent inhibition that was used for calculations (includes all concentration points); in some cases a data point can be excluded as outlier.Integer
11Inhibition at 4.0 nM (0.004μM**)Value of %inhibition at 4.0 nM inhibitor concentration; average of triplicate measurement.Float%
12Inhibition at 12.1 nM (0.0121μM**)Value of %inhibition at 12.1 nM inhibitor concentration; average of triplicate measurement.Float%
13Inhibition at 36.3 nM (0.0363μM**)Value of %inhibition at 36.3 nM inhibitor concentration; average of triplicate measurement.Float%
14Inhibition at 108.9 nM (0.1089μM**)Value of %inhibition at 108.9 nM inhibitor concentration; average of triplicate measurement.Float%
15Inhibition at 326.6 nM (0.3266μM**)Value of %inhibition at 326.6 nM inhibitor concentration; average of triplicate measurement.Float%
16Inhibition at 979.8 nM (0.9798μM**)Value of %inhibition at 979.8 nM inhibitor concentration; average of triplicate measurement.Float%
17Inhibition at 2.9 uM (2.9μM**)Value of %inhibition at 2.9 micromolar inhibitor concentration; average of triplicate measurement.Float%
18Inhibition at 8.8 uM (8.8μM**)Value of %inhibition at 8.8 micromolar inhibitor concentration; average of triplicate measurement.Float%
19Inhibition at 26.5 uM (26.5μM**)Value of %inhibition at 26.5 micromolar inhibitor concentration; average of triplicate measurement.Float%
20Inhibition at 79.4 uM (79.4μM**)Value of %inhibition at 79.4 micromolar inhibitor concentration; average of triplicate measurement.Float%

* Activity Concentration. ** Test Concentration.
Additional Information
Grant Number: 1 R03 MH085690-01

Data Table (Concise)
PageFrom: